NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

JBIO

Jade Biosciences Inc

Jul 03 • 02:20PM ET

11.14

Dollar change +0.34
Percentage change 3.15	%

Healthcare • Biotechnology • USA • NASD

Peers: VRTX BLUE CORT FATE BMRN CRSP RGNX EDIT AGIO NTLA

| Held by: IWM IWN IWC RSSL VTI OMFS VXF UWM URTY VTWO

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-59.44	Insider Own	16.20%	Shs Outstand	32.24M	Perf Week	20.43%
Market Cap	359.11M	Forward P/E	-	EPS next Y	-2.12	Insider Trans	0.12%	Shs Float	27.01M	Perf Month	53.66%
Enterprise Value	283.21M	PEG	-	EPS next Q	-0.69	Inst Own	34.81%	Short Float	1.41%	Perf Quarter	20.89%
Income	-48.96M	P/S	-	EPS this Y	95.66%	Inst Trans	17.94%	Short Ratio	0.98	Perf Half Y	14.53%
Sales	0.00M	P/B	0.12	EPS next Y	15.28%	ROA	-53.12%	Short Interest	0.38M	Perf YTD	14.96%
Book/sh	90.62	P/C	4.71	EPS next 5Y	64.67%	ROE	-59.01%	52W High	13.50 -17.49%	Perf Year	79.20%
Cash/sh	2.36	P/FCF	-	EPS past 3/5Y	-37.28% -77.98%	ROIC	-65.24%	52W Low	5.74 94.04%	Perf 3Y	-79.65%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	12.82% 12.27%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	44.04%	Oper. Margin	-	ATR (14)	1.02	Perf 10Y	-
Dividend Ex-Date	Apr 29, 2025	Quick Ratio	32.01	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	68.65	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	32.01	EPS Q/Q	89.59%	SMA20	26.42%	Beta	0.91	Target Price	16.67
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	28.49%	Rel Volume	0.28	Prev Close	10.80
Employees	30	LT Debt/Eq	0.00	Earnings	May 14 AMC	SMA200	24.99%	Avg Volume	389.11K	Price	11.14
IPO	Jun 30, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	-100.83% -	Trades		Volume	110,749	Change	3.15%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-16-25	Upgrade	Guggenheim	Neutral → Buy	$14
May-07-25	Initiated	Wedbush	Outperform	$17
May-05-25	Initiated	Stifel	Buy	$19
May-02-25	Initiated	TD Cowen	Buy	$10
Jun-18-24	Downgrade	Wells Fargo	Overweight → Equal Weight	$35 → $2
Jun-18-24	Downgrade	TD Cowen	Buy → Hold
Jun-18-24	Downgrade	Evercore ISI	Outperform → In-line	$27 → $2
Jun-17-24	Downgrade	Wedbush	Outperform → Neutral	$41 → $3
Jun-17-24	Downgrade	Guggenheim	Buy → Neutral
Jun-17-24	Downgrade	BTIG Research	Buy → Neutral
Mar-25-24	Resumed	Jefferies	Buy	$21 → $65
Dec-08-23	Initiated	Wells Fargo	Equal Weight	$35
Mar-01-23	Initiated	Guggenheim	Buy	$36
Dec-06-22	Upgrade	BTIG Research	Neutral → Buy	$27
Sep-19-22	Resumed	Wedbush	Outperform	$27
Aug-16-22	Downgrade	BTIG Research	Buy → Neutral
Feb-11-22	Initiated	BTIG Research	Buy	$24
Jul-26-21	Initiated	Wedbush	Outperform	$23
Jul-26-21	Initiated	Jefferies	Buy	$21
Jul-26-21	Initiated	Evercore ISI	Outperform	$30

Show Previous Ratings

Jul-01-25 07:00AM	Jade Biosciences Appoints Brad Dahms as Chief Financial Officer (GlobeNewswire) +8.56%
Jun-24-25 07:30AM	2 Small-Cap Stocks Under $10 to Buy With Big Potential (Barchart) +6.18%
Jun-09-25 07:00AM	Jade Biosciences Presents JADE101 Preclinical Data at the 62nd European Renal Association Congress Demonstrating Potential for Best-in-Class Profile in IgA Nephropathy (GlobeNewswire) +7.23%
Jun-02-25 07:00AM	Jade Biosciences to Present New Preclinical Data on JADE101 at the 62nd European Renal Association Congress (GlobeNewswire)
May-14-25 04:05PM	Jade Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire) -12.31%
07:00AM	Loading…
May-13-25 07:00AM	Jade Biosciences to Participate in the 2025 Jefferies Global Healthcare Conference (GlobeNewswire)
Apr-26-25 11:00AM	Microsoft, Apple Set To Report Earnings As Markets Watch Out For Core PCE Price Index (Seeking Alpha)
Apr-21-25 08:00AM	Aerovate Therapeutics Stockholders Approve Proposed Merger with Jade Biosciences and All Related Proposals (PR Newswire)
Apr-09-25 04:05PM	Aerovate Therapeutics Declares Special Cash Dividend in Connection with the Proposed Merger with Jade Biosciences (PR Newswire)
Apr-07-25 08:30AM	Aerovate Therapeutics Announces Range of Expected Cash Dividend in Connection with the Proposed Merger with Jade Biosciences (PR Newswire)
Oct-31-24 08:18AM	Jade, another biotech spinout of Paragon, to merge with Aerovate (BioPharma Dive) +11.87%
07:00AM	Aerovate Therapeutics and Jade Biosciences Announce Merger Agreement (GlobeNewswire)
Jul-08-24 08:00AM	Ligand to buy Apeiron; Roche reports another TIGIT setback (BioPharma Dive) +8.07%
08:00AM	Aerovate Therapeutics to Explore Strategic Alternatives (GlobeNewswire)
Jul-02-24 01:13PM	Aerovate slashes workforce after failed Phase IIb trial (Clinical Trials Arena)
07:00AM	Loading…
Jun-27-24 07:00AM	The 3 Hottest Stock Downgrades From Last Week (InvestorPlace) +15.97%
Jun-18-24 09:21AM	Aerovate (AVTE) Down as Lead Drug Fails to Meet PAH Study Goals (Zacks) -14.55%
Jun-17-24 04:11PM	Aerovate Therapeutics Stock Dropped Over 90%. Heres Why. (Barrons.com) -93.30%
04:04PM	Why 93% Of Aerovate Therapeutics' Value Just Went Up In Smoke (Investor's Business Daily)
08:32AM	Aerovate Therapeutics Announces 24-Week Topline Results from the Phase 2b Portion of IMPAHCT Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension (GlobeNewswire)
May-21-24 04:15PM	Aerovate Therapeutics Presents Baseline Data from the Phase 2b Portion of the IMPAHCT Trial at the American Thoracic Society 2024 International Conference (GlobeNewswire) -9.04%
May-13-24 09:54PM	AVTE Stock Earnings: Aerovate Therapeutics Misses EPS for Q1 2024 (InvestorPlace)
04:30PM	Aerovate Therapeutics Announces First Quarter Financial Results and Business Highlights (GlobeNewswire)
Apr-04-24 01:31AM	Aerovate Therapeutics Inc CEO Timothy Noyes Sells 10,000 Shares (GuruFocus.com)
Mar-27-24 09:20AM	Aerovate Therapeutics to Present Patient Baseline Characteristics of the Phase 2b Portion of the Phase 2b/Phase 3 IMPAHCT Trial at the American Thoracic Society 2024 International Conference (GlobeNewswire) +11.11%
Mar-26-24 09:01PM	Aerovate Therapeutics Inc (AVTE) Reports Increased R&D Expenses and Net Loss in 2023 (GuruFocus.com)
Mar-25-24 09:53PM	AVTE Stock Earnings: Aerovate Therapeutics Misses EPS for Q4 2023 (InvestorPlace)
04:10PM	Aerovate Therapeutics Announces Full-Year 2023 Financial Results and Business Highlights (GlobeNewswire)
Mar-21-24 02:32AM	Chief Medical Officer Hunter Gillies Sells 7,000 Shares of Aerovate Therapeutics Inc (AVTE) (GuruFocus.com)
02:32AM	Insider Sell: Aerovate Therapeutics Inc's (AVTE) Chief Technical Officer Marinus Verwijs Sells ... (GuruFocus.com)
08:00AM	Loading…
Mar-06-24 08:00AM	Aerovate Therapeutics Board of Directors Appoints Habib Dable as Board Chair (GlobeNewswire)
Dec-16-23 11:01AM	Insider Sell Alert: Chief Medical Officer Hunter Gillies Sells 12,000 Shares of Aerovate ... (GuruFocus.com)
Nov-20-23 04:45PM	Aerovate Therapeutics Announces Simultaneous Completion of Enrollment in Phase 2b Portion and Enrollment of First Patient into Phase 3 in the IMPAHCT Trial Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension (GlobeNewswire)
Nov-13-23 11:09AM	Aerovate Therapeutics Inc Reports Increased R&D Expenses and Net Loss in Q3 (GuruFocus.com) +8.45%
08:00AM	Aerovate Therapeutics Announces Third Quarter Financial Results and Business Highlights (GlobeNewswire)
Oct-30-23 09:32AM	12 Best Micro Cap Stocks To Invest In (Insider Monkey)
Sep-19-23 05:07AM	Down More Than 50%: 2 Strong Buy Stocks That Are Too Cheap to Ignore (TipRanks)
Aug-28-23 08:20AM	TENX: Second Quarter Results (Zacks)
Aug-14-23 08:00AM	Aerovate Therapeutics Announces Second Quarter Financial Results and Business Highlights (GlobeNewswire)
Jul-22-23 09:29AM	Aerovate Therapeutics (NASDAQ:AVTE) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
Jul-11-23 05:00PM	Aerovate Therapeutics Appoints Habib Dable To Its Board of Directors (GlobeNewswire)
Jun-23-23 06:24AM	TENX: Notice of Allowance Increases Confidence (Zacks Small Cap Research)
Jun-01-23 08:00AM	Aerovate Therapeutics to Present at Jefferies Global Healthcare Conference (GlobeNewswire)
May-22-23 01:15PM	Aerovate Therapeutics Presents Nonclinical Pharmacokinetic Data in Support of AV-101, a Novel Dry Powder Inhaled Formulation of Imatinib, at the American Thoracic Society (ATS) 2023 International Conference (GlobeNewswire)
May-15-23 04:05PM	Aerovate Therapeutics Announces First Quarter Financial Results and Business Highlights (GlobeNewswire) -7.45%
Mar-29-23 04:50PM	Aerovate Therapeutics Announces Full-Year 2022 Financial Results and Business Highlights (GlobeNewswire)
Mar-02-23 08:00AM	Aerovate Therapeutics to Present at Cowen 43rd Annual Health Care Conference (GlobeNewswire)
Feb-12-23 08:07AM	We Think Aerovate Therapeutics (NASDAQ:AVTE) Can Afford To Drive Business Growth (Simply Wall St.)
Jan-23-23 08:00AM	Aerovate Therapeutics Appoints Donald Santel To Its Board of Directors (GlobeNewswire)
Dec-31-22 08:22AM	Calculating The Fair Value Of Aerovate Therapeutics, Inc. (NASDAQ:AVTE) (Simply Wall St.)
Dec-28-22 10:15PM	12 Best Performing Biotech Stocks in 2022 (Insider Monkey)
Dec-06-22 01:19PM	Analyst Turns Bullish On Aerovate As Competitor Data Reinforce Lead Program Thesis (Benzinga)
Nov-17-22 07:45AM	Aerovate Therapeutics Publishes Results of Phase 1 Study Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension in ERJ Open Research (GlobeNewswire)
Nov-14-22 07:45AM	Aerovate Therapeutics Announces Third Quarter 2022 Financial Results (GlobeNewswire)
Oct-18-22 08:00AM	Aerovate Therapeutics Presents Novel Phase 2b/Phase 3 IMPAHCT Trial Design at CHEST Annual Meeting 2022 (GlobeNewswire) +5.28%
Sep-05-22 07:17AM	Aerovate Therapeutics (NASDAQ:AVTE) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
Aug-15-22 07:50AM	Aerovate Therapeutics Announces Second Quarter 2022 Financial Results (GlobeNewswire)
Jun-02-22 08:00AM	Aerovate Therapeutics to Present at Jefferies Global Healthcare Conference (GlobeNewswire)
May-16-22 05:15PM	Aerovate Therapeutics Presents Phase 1 Data for AV-101, A Novel Dry Powder Inhaled Formulation of Imatinib Being Developed for the Treatment of Patients with Pulmonary Arterial Hypertension (PAH) (GlobeNewswire) -11.25% +5.60%
08:00AM	Aerovate Therapeutics Announces First Quarter 2022 Financial Results (GlobeNewswire)
Mar-30-22 04:45PM	Aerovate Therapeutics Announces Full-Year 2021 Financial Results (GlobeNewswire) +5.72%
Mar-29-22 11:42AM	We Think Aerovate Therapeutics (NASDAQ:AVTE) Can Afford To Drive Business Growth (Simply Wall St.) +11.35%
Mar-02-22 08:00AM	Aerovate Therapeutics to Present at Cowen 42nd Annual Health Care Conference (GlobeNewswire) +7.32%
Dec-15-21 08:00AM	Aerovate Therapeutics Announces Initiation of IMPAHCT Phase 2b/Phase 3 Trial of AV-101 In Pulmonary Arterial Hypertension (GlobeNewswire) +16.31%
Nov-25-21 07:35AM	15 Pharmaceutical Stocks to Buy According to Peter Kolchinskys RA Capital (Insider Monkey)
Nov-15-21 08:00AM	Aerovate Therapeutics Announces Third Quarter 2021 Financial Results (GlobeNewswire) -18.94%
Sep-30-21 06:40AM	Here's Why We're Not Too Worried About Aerovate Therapeutics' (NASDAQ:AVTE) Cash Burn Situation (Simply Wall St.)
Sep-21-21 05:05AM	48 Biggest Movers From Yesterday (Benzinga)
Sep-17-21 08:00AM	Aerovate Therapeutics Announces Its Addition to the Russell 2000® Index (GlobeNewswire)
Aug-16-21 08:00AM	Aerovate Therapeutics Announces Second Quarter 2021 Financial Results (GlobeNewswire)
Jul-19-21 08:00AM	Aerovate Therapeutics Appoints Allison Dorval To Its Board of Directors (GlobeNewswire)
Jul-02-21 04:01PM	Aerovate Therapeutics Announces Closing of Initial Public Offering with Exercise in Full of the Underwriters Option to Purchase Additional Shares (GlobeNewswire) -5.37%
Jun-29-21 10:59PM	Aerovate Therapeutics Announces Pricing of Upsized Initial Public Offering (GlobeNewswire)

Jade Biosciences, Inc. is a biotechnology company which engages in the development of drugs for rare cardiopulmonary disease. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension. The company was founded by Benjamin T. Dake on July 27, 2018 and is headquartered in Waltham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Atlas Venture Fund XII, L.P.	Shareholder	Jun 25 '25	Proposed Sale	10.48	28,977	303,679		Jun 25 05:37 PM
Atlas Venture Associates XII,	Shareholder	Jun 25 '25	Proposed Sale	10.48	235	2,463		Jun 25 05:31 PM
Atlas Venture Fund XII, L.P.	Shareholder	Jun 24 '25	Proposed Sale	9.87	16,132	159,223		Jun 24 05:03 PM
Atlas Venture Associates XII,	Shareholder	Jun 24 '25	Proposed Sale	9.87	131	1,293		Jun 24 04:59 PM
Frohlich Tom	Chief Executive Officer	May 16 '25	Buy	7.40	6,000	44,400	6,000	May 19 04:54 PM
Atlas Venture Associates XII,	Shareholder	May 06 '25	Proposed Sale	11.50	48	552		May 06 05:14 PM
Atlas Venture Fund XII, L.P.	Shareholder	May 06 '25	Proposed Sale	11.50	5,883	67,654		May 06 05:11 PM
Dake Benjamin T	SEE REMARKS	Jul 31 '24	Option Exercise	1.74	11,454	19,930	12,745	Aug 02 06:00 PM
Dake Benjamin T	SEE REMARKS	Aug 01 '24	Option Exercise	1.74	1,507	2,622	14,252	Aug 02 06:00 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

JBIO

Jade Biosciences Inc

Upgrade your FINVIZ experience